COMMUNIQUÉS West-GlobeNewswire

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
30/07/2026
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective therapies for [...]
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
30/07/2026
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support [...]
PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026
30/07/2026
DELRAY BEACH, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the first quarter fiscal year [...]
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
30/07/2026
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling More than 70% of patients do not [...]
Glow Peptide Stack Launched by Kylo Peptides for Laboratory Use
30/07/2026
Sheridan, Wyoming , July 30, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides has announced that it has added the GLOW peptide stack to its research catalog. The product supplies three separately sealed, lyophilized vials of the [...]
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
30/07/2026
As of July 29, 2026, trading volume on the Rain protocol reached $860MM 1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. ( [...]
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
30/07/2026
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
30/07/2026
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment [...]
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
30/07/2026
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technology KANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- [...]
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia
30/07/2026
Partnership with Cure HHT strengthens patient engagement and supports streamlined clinical trial execution Harmony-HHT Phase 1/2 trial activates first clinical site at Massachusetts General Hospital, marking an [...]
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
30/07/2026
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of [...]
NewGen Provides Update on K25.ai Investment and Strengthened Financial Position
30/07/2026
NewGen’s total shares outstanding count expected to reach 5.9 million following recently announced share issuance, bolstering market capitalization NewGen’s agreed 13% stake in K25.ai is now valued at approximately US$ [...]
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
30/07/2026
SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
30/07/2026
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutation following [...]
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
30/07/2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR- [...]
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
30/07/2026
Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab [...]
Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
30/07/2026
Lite Strategy Buys Back Roughly 4.9 Million Shares at an Average Price of $1.11 with No Debt Incurred SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), [...]
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
30/07/2026
Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate Development MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or [...]
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
30/07/2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of [...]

Pages